scholarly journals BDNF Genetic Variant and Its Genotypic Fluctuation in Major Depressive Disorder

2021 ◽  
Vol 2021 ◽  
pp. 1-16
Author(s):  
Caroline Ferreira Fratelli ◽  
Jhon Willatan Siqueira ◽  
Bruna Rodrigues Gontijo ◽  
Maurício de Lima Santos ◽  
Calliandra Maria de Souza Silva ◽  
...  

Major depressive disorder (MDD) still has an unknown etiology and mechanisms. Many studies have been conducted seeking to associate and understand the connection of different genetic variants to this disease. Researchers have extensively studied the brain-derived neurotrophic factor (BDNF) Val66Met genetic variant in MDD; yet, their findings remain inconsistent. This systematic review sought to verify the GG (Val/Val) genotype frequency fluctuation in different populations with MDD. For this, we searched in different databases and, after applying the eligibility criteria, selected 17 articles. Most studies demonstrate the higher frequency of the ancestral (wild) GG (Val/Val) genotype, although associations of the polymorphic A (Met) allele, changes in BDNF protein serum levels, or both were also found in MDD, whether related to the disease’s development or other factors. Nevertheless, despite these findings, disagreements between several studies are seen. For this reason, further BDNF Val66Met genetic variant studies should not only bridge the gap in the knowledge of this polymorphism’s role in MDD’s different facets but also analyze the genotypic and phenotypic heterogeneity in different populations to help provide a better quality of life for patients.

2021 ◽  
Author(s):  
Emma Morton ◽  
Venkat Bhat ◽  
Peter Giacobbe ◽  
Wendy Lou ◽  
Erin E. Michalak ◽  
...  

Abstract Introduction Many individuals with major depressive disorder (MDD) do not respond to initial antidepressant monotherapy. Adjunctive aripiprazole is recommended for treatment non-response; however, the impacts on quality of life (QoL) for individuals who receive this second-line treatment strategy have not been described. Methods We evaluated secondary QoL outcomes in patients with MDD (n=179). After 8 weeks of escitalopram, non-responders (<50% decrease in clinician-rated depression) were treated with adjunctive aripiprazole for 8 weeks (n=97); responders continued escitalopram (n=82). A repeated-measures ANOVA evaluated change in Quality of Life Enjoyment and Satisfaction Short Form scores. QoL was described relative to normative benchmarks. Results Escitalopram responders experienced the most QoL improvements in the first treatment phase. For non-responders, QoL improved with a large effect during adjunctive aripiprazole treatment. At the endpoint, 47% of patients achieving symptomatic remission still had impaired QoL. Discussion Individuals who were treated with adjunctive aripiprazole after non-response to escitalopram experienced improved QoL, but a substantial degree of QoL impairment persisted. Since QoL deficits may predict MDD recurrence, attention to ways to support this outcome is required.


2013 ◽  
Vol 30 (7) ◽  
pp. 697-712 ◽  
Author(s):  
Claudio Mencacci ◽  
Eugenio Aguglia ◽  
Giovanni Biggio ◽  
Lodovico Cappellari ◽  
Guido Di Sciascio ◽  
...  

2016 ◽  
Vol 12 (3) ◽  
pp. 719-736
Author(s):  
Alexander Joseph Steiner ◽  
Stephanie Marie Wright ◽  
Taylor Kuhn ◽  
Waguih William IsHak

2009 ◽  
Vol 11 (6) ◽  
pp. 503-508 ◽  
Author(s):  
Waguih William IsHak ◽  
Michael Davis ◽  
Jessica Jeffrey ◽  
Konstantin Balayan ◽  
Robert N. Pechnick ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document